Possible role of plasma Galectin-9 levels as a surrogate marker of viremia in HIV infected patients on antiretroviral therapy in resource-limited settings.

Ashwnini SheteSampada DhayarkarAshwini DhamanageSmita KulkarniManisha GhateShashikala SangleUttam MedheVinita VermaShobini RajanToshio HattoriRaman Gangakhedkar

Published in: AIDS research and therapy (2020)

Plasma Galectin-9 levels could identify viremic individuals with sensitivity and specificity of more than 90%. Thus, they showed a potential to serve as a surrogate marker of viremia in HIV infected patients on ART and would have cost implications on HIV management especially in resource-limited settings. However, the findings need to be confirmed in the patients on ART for different durations of time.

Keyphrases

antiretroviral therapy
hiv infected patients
hiv infected
hiv positive
human immunodeficiency virus
hiv aids
end stage renal disease
newly diagnosed
ejection fraction
peritoneal dialysis
prognostic factors
patient reported outcomes
risk assessment
hiv testing
men who have sex with men